1801 Augustine Cut-Off
About Incyte Corporation
Drug Discovery & Development
Since we began our drug-discovery and development activities in early 2002, we have filed Investigational New Drug (IND) applications and progressed multiple internally developed proprietary compounds into clinical development. In late 2011, we received our first US Food and Drug Administration approval for Jakafi® (ruxolitinib), a JAK1 and JAK2 inhibitor.
Incyte has an exceptional team of drug discovery and development scientists led by distinguished executives with proven records of success and many scientific and clinical achievements. We employ only the best and those who adhere to the highest standards of scientific and clinical rigor, and we resource our programs for success. We have a strong discovery team that is tightly integrated with all disciplines, including development, regulatory, and commercial operations. Our therapeutic focus is primarily on oncology.
One Molecule at a Time
464 articles with Incyte Corporation
Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo
Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream
Incyte Corporation announced that it has scheduled its third quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, October 29, 2019.
CORRECTING and REPLACING Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Incyte (Nasdaq:INCY) announces updated results, including the final result for the primary endpoint, from its Phase 2 FIGHT-202 trial evaluating pemigatinib, a selective fibroblast growth factor receptor (FGFR) inhibitor, as a treatment for patients with previously treated, locally advanced or metastatic cholangiocarcinoma.
Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma
Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
Updated Phase 2 results from the FIGHT-202 study highlight the potential of pemigatinib as a treatment option for patients with previously treated, advanced cholangiocarcinoma
9/3/2019Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.
The investigational JAK inhibitor has hit the mark in three late-stage studies, with readouts from two more late-stage trials expected later this year.
Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis
Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial in the BREEZE-AD program to be completed in 2019.
Incyte Corporation announced that it will present at the following investor conferences during the month of September
Incyte Corporation reports 2019 second quarter financial results and provides a status update on the Company’s development portfolio.
The award recognizes individuals and organizations who are making a difference in the myeloproliferative neoplasm community
Incyte Corporation announced that it has scheduled its second quarter 2019 financial results conference call and webcast for 8:00 a.m. ET on Tuesday, July 30, 2019.
Collaboration will expand potential to bring new medicines to patients with cancer around the world
With more than 16,000 attendees from 67 countries and hundreds, even thousands of presentations, it can be difficult to get a real grip on everything that went on at the 2019 BIO International Convention held in Philadelphia. Here’s a look at just a few of the highlights.
The approval of Jakafi marks the first approved treatment for this indication in the United States.
For young people looking to find a career path, the pharmaceutical industry is a good one to go into, especially if salary is a major concern.
FDA Approves Jakafi® (ruxolitinib) for the Treatment of Patients with Acute Graft-Versus-Host Disease
Jakafi is the first and only FDA-approved treatment for patients with steroid-refractory acute graft-versus-host disease (GVHD)
Incyte Corporation announced that it will present at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019 at 2:00 pm / 5:00 pm in Rancho Palos Verdes.
Data from Incyte’s Inflammation and Autoimmunity Portfolio to be Featured at the 24th World Congress of Dermatology
Investor conference call and webcast scheduled for Monday, June 17 at 8 a.m. EDT